ORTHO CLINICAL DIAGNOSTICS H (OCDX) Stock Price, Quote, News and Overview
NASDAQ:OCDX - Nasdaq - GB00BMDNH979 - Common Stock
OCDX Quote, Performance and Key Statistics
NASDAQ:OCDX (5/26/2022, 8:13:30 PM)
17.63
+0.08 (+0.46%)
The current stock price of OCDX is 17.63 null. In the past month the price increased by 0.23%. In the past year, price decreased by -14.21%.
OCDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About OCDX
Company Profile
Ortho Clinical Diagnostics Holdings Plc provides vitro diagnostics services. The company is headquartered in Raritan, New Jersey and currently employs 4,800 full-time employees. The company went IPO on 2021-01-28. The firm provides laboratory testing and blood-typing solutions to the clinical laboratory and transfusion medicine communities. The firm provides customized solutions for clinical outcomes, lab performance and staffing challenges. The firm operates through two lines of business such as Clinical Laboratories and Transfusion Medicine. Its Clinical Laboratories business focuses on clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across therapeutic areas. The Transfusion Medicine business is focused on immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions. Its Donor Screening business is focused on instruments and tests used for blood and plasma screening for infectious diseases for customers, which include some of the donor testing institutions.
Company Info
ORTHO CLINICAL DIAGNOSTICS H
1001 Route 202
Raritan NEW JERSEY 08869 US
CEO: Chris Smith
Employees: 4800
Company Website: https://www.orthoclinicaldiagnostics.com/
Phone: 19082188000.0
ORTHO CLINICAL DIAGNOSTICS H / OCDX FAQ
What is the stock price of ORTHO CLINICAL DIAGNOSTICS H today?
The current stock price of OCDX is 17.63 null. The price increased by 0.46% in the last trading session.
What is the ticker symbol for ORTHO CLINICAL DIAGNOSTICS H stock?
The exchange symbol of ORTHO CLINICAL DIAGNOSTICS H is OCDX and it is listed on the Nasdaq exchange.
On which exchange is OCDX stock listed?
OCDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORTHO CLINICAL DIAGNOSTICS H stock?
11 analysts have analysed OCDX and the average price target is 21.74 null. This implies a price increase of 23.3% is expected in the next year compared to the current price of 17.63. Check the ORTHO CLINICAL DIAGNOSTICS H stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORTHO CLINICAL DIAGNOSTICS H worth?
ORTHO CLINICAL DIAGNOSTICS H (OCDX) has a market capitalization of 4.19B null. This makes OCDX a Mid Cap stock.
How many employees does ORTHO CLINICAL DIAGNOSTICS H have?
ORTHO CLINICAL DIAGNOSTICS H (OCDX) currently has 4800 employees.
What are the support and resistance levels for ORTHO CLINICAL DIAGNOSTICS H (OCDX) stock?
ORTHO CLINICAL DIAGNOSTICS H (OCDX) has a support level at 17.62 and a resistance level at 17.95. Check the full technical report for a detailed analysis of OCDX support and resistance levels.
Is ORTHO CLINICAL DIAGNOSTICS H (OCDX) expected to grow?
The Revenue of ORTHO CLINICAL DIAGNOSTICS H (OCDX) is expected to grow by 1.8% in the next year. Check the estimates tab for more information on the OCDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORTHO CLINICAL DIAGNOSTICS H (OCDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OCDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OCDX, evaluating the profitability, health, valuation and growth aspects
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Sales and EPS estimates to see what analysts future expectations are.
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Stock Chart to make your own analysis
- ORTHO CLINICAL DIAGNOSTICS H (OCDX) Latest news and press-releases to stay up to date.
Does ORTHO CLINICAL DIAGNOSTICS H (OCDX) stock pay dividends?
OCDX does not pay a dividend.
When does ORTHO CLINICAL DIAGNOSTICS H (OCDX) report earnings?
ORTHO CLINICAL DIAGNOSTICS H (OCDX) will report earnings on 2022-08-02.
What is the Price/Earnings (PE) ratio of ORTHO CLINICAL DIAGNOSTICS H (OCDX)?
The PE ratio for ORTHO CLINICAL DIAGNOSTICS H (OCDX) is 21.77. This is based on the reported non-GAAP earnings per share of 0.81 and the current share price of 17.63 null. Check the full fundamental report for a full analysis of the valuation metrics for OCDX.
OCDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OCDX. When comparing the yearly performance of all stocks, OCDX turns out to be only a medium performer in the overall market: it outperformed 50.31% of all stocks.
OCDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCDX. There are concerns on the financial health of OCDX while its profitability can be described as average.
OCDX Financial Highlights
Over the last trailing twelve months OCDX reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 99.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -0.02% | ||
| ROA | -0.01% | ||
| ROE | N/A | ||
| Debt/Equity | 4.91 |
OCDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to OCDX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 11.82% and a revenue growth 1.8% for OCDX